| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 466 | 2024 | 5146 | 25.230 |
Why?
|
| Neoplasm, Residual | 20 | 2024 | 1008 | 3.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 67 | 2024 | 8554 | 3.140 |
Why?
|
| Thalidomide | 50 | 2021 | 885 | 2.690 |
Why?
|
| Boronic Acids | 67 | 2024 | 915 | 2.500 |
Why?
|
| B-Cell Maturation Antigen | 17 | 2024 | 149 | 2.350 |
Why?
|
| Plasma Cells | 23 | 2023 | 599 | 2.320 |
Why?
|
| Pyrazines | 67 | 2024 | 1202 | 2.220 |
Why?
|
| Paraproteinemias | 12 | 2022 | 248 | 2.080 |
Why?
|
| Dexamethasone | 51 | 2024 | 1948 | 2.080 |
Why?
|
| Antineoplastic Agents | 105 | 2024 | 13642 | 2.030 |
Why?
|
| Immunotherapy, Adoptive | 19 | 2024 | 1469 | 1.970 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 77 | 2024 | 11742 | 1.930 |
Why?
|
| Drug Resistance, Neoplasm | 46 | 2024 | 5305 | 1.930 |
Why?
|
| Cell Line, Tumor | 125 | 2024 | 16990 | 1.850 |
Why?
|
| Neoplasms, Plasma Cell | 5 | 2023 | 39 | 1.750 |
Why?
|
| Syndecan-1 | 11 | 2020 | 163 | 1.740 |
Why?
|
| Mice, SCID | 63 | 2021 | 2626 | 1.620 |
Why?
|
| T-Lymphocytes, Cytotoxic | 12 | 2024 | 1784 | 1.590 |
Why?
|
| Waldenstrom Macroglobulinemia | 22 | 2023 | 1073 | 1.540 |
Why?
|
| Neoplasm Proteins | 25 | 2022 | 3617 | 1.490 |
Why?
|
| Sp1 Transcription Factor | 5 | 2016 | 140 | 1.430 |
Why?
|
| Apoptosis | 96 | 2022 | 9490 | 1.370 |
Why?
|
| Humans | 567 | 2024 | 761596 | 1.250 |
Why?
|
| Cell Proliferation | 69 | 2023 | 10451 | 1.250 |
Why?
|
| Oligopeptides | 7 | 2024 | 1187 | 1.200 |
Why?
|
| Bone Marrow | 38 | 2023 | 2911 | 1.200 |
Why?
|
| Genomic Instability | 11 | 2024 | 709 | 1.180 |
Why?
|
| Antibodies, Monoclonal | 33 | 2022 | 9177 | 1.180 |
Why?
|
| Stem Cell Transplantation | 15 | 2022 | 1600 | 1.140 |
Why?
|
| Bone Marrow Cells | 34 | 2024 | 2417 | 1.120 |
Why?
|
| Tumor Cells, Cultured | 76 | 2021 | 6131 | 1.080 |
Why?
|
| MicroRNAs | 17 | 2023 | 3816 | 1.060 |
Why?
|
| Telomerase | 13 | 2013 | 745 | 1.050 |
Why?
|
| Melphalan | 22 | 2024 | 420 | 1.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 7 | 2022 | 587 | 1.040 |
Why?
|
| Translocation, Genetic | 14 | 2023 | 1393 | 1.010 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 7 | 2021 | 179 | 0.980 |
Why?
|
| HSP90 Heat-Shock Proteins | 8 | 2015 | 424 | 0.970 |
Why?
|
| High-Throughput Nucleotide Sequencing | 14 | 2021 | 3639 | 0.960 |
Why?
|
| Dendritic Cells | 15 | 2023 | 2747 | 0.950 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 38 | 2023 | 5672 | 0.950 |
Why?
|
| DNA-Binding Proteins | 29 | 2020 | 9610 | 0.950 |
Why?
|
| Cell Survival | 42 | 2018 | 5791 | 0.900 |
Why?
|
| Tumor Microenvironment | 17 | 2024 | 3878 | 0.890 |
Why?
|
| Immunotherapy | 16 | 2024 | 4652 | 0.880 |
Why?
|
| Mutation | 39 | 2024 | 30053 | 0.860 |
Why?
|
| Gene Expression Profiling | 44 | 2021 | 9420 | 0.850 |
Why?
|
| Histone Deacetylase Inhibitors | 12 | 2018 | 774 | 0.840 |
Why?
|
| Diphosphonates | 10 | 2015 | 635 | 0.830 |
Why?
|
| Osteoclasts | 14 | 2018 | 711 | 0.820 |
Why?
|
| Transplantation, Autologous | 26 | 2023 | 2115 | 0.810 |
Why?
|
| Receptors, Interleukin-4 | 2 | 2021 | 64 | 0.800 |
Why?
|
| Prognosis | 59 | 2024 | 29629 | 0.790 |
Why?
|
| 14-3-3 Proteins | 2 | 2020 | 220 | 0.790 |
Why?
|
| Stromal Cells | 34 | 2024 | 1330 | 0.790 |
Why?
|
| Enzyme Inhibitors | 26 | 2013 | 3713 | 0.780 |
Why?
|
| Imidazoles | 12 | 2015 | 1180 | 0.780 |
Why?
|
| Oncogenes | 6 | 2021 | 1222 | 0.760 |
Why?
|
| Veterans | 6 | 2024 | 2649 | 0.740 |
Why?
|
| Enhancer Elements, Genetic | 5 | 2018 | 1363 | 0.730 |
Why?
|
| Xenograft Model Antitumor Assays | 40 | 2021 | 3605 | 0.730 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 3 | 2019 | 200 | 0.730 |
Why?
|
| Immunologic Factors | 16 | 2023 | 1590 | 0.720 |
Why?
|
| Plasmacytoma | 5 | 2021 | 171 | 0.720 |
Why?
|
| Protease Inhibitors | 17 | 2012 | 754 | 0.720 |
Why?
|
| Transcription Factors | 24 | 2020 | 12130 | 0.720 |
Why?
|
| Proteasome Endopeptidase Complex | 19 | 2023 | 1321 | 0.690 |
Why?
|
| Dependovirus | 8 | 2002 | 718 | 0.690 |
Why?
|
| Transcriptional Activation | 5 | 2014 | 1756 | 0.690 |
Why?
|
| Bone Density Conservation Agents | 9 | 2021 | 795 | 0.680 |
Why?
|
| p21-Activated Kinases | 2 | 2018 | 128 | 0.670 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2024 | 634 | 0.670 |
Why?
|
| Interleukin-4 | 3 | 2021 | 1149 | 0.670 |
Why?
|
| Mice | 113 | 2024 | 81539 | 0.660 |
Why?
|
| Hydroxamic Acids | 9 | 2016 | 481 | 0.650 |
Why?
|
| Disease-Free Survival | 26 | 2024 | 6815 | 0.640 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2023 | 9280 | 0.640 |
Why?
|
| Interleukin-17 | 3 | 2015 | 912 | 0.640 |
Why?
|
| DNA Damage | 10 | 2021 | 2449 | 0.620 |
Why?
|
| NF-kappa B | 30 | 2021 | 2490 | 0.620 |
Why?
|
| Osteolysis | 5 | 2015 | 275 | 0.620 |
Why?
|
| Interleukin-6 | 37 | 2015 | 3208 | 0.610 |
Why?
|
| Immunoconjugates | 7 | 2021 | 953 | 0.600 |
Why?
|
| Genomics | 16 | 2023 | 5821 | 0.600 |
Why?
|
| Cell Cycle | 24 | 2024 | 2932 | 0.590 |
Why?
|
| Alternative Splicing | 2 | 2022 | 1093 | 0.590 |
Why?
|
| Telomere | 10 | 2013 | 943 | 0.590 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 10 | 2017 | 1651 | 0.580 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2018 | 710 | 0.580 |
Why?
|
| Animals | 134 | 2024 | 168475 | 0.580 |
Why?
|
| Monocytes | 3 | 2023 | 2570 | 0.580 |
Why?
|
| DNA Copy Number Variations | 7 | 2021 | 2020 | 0.580 |
Why?
|
| Ubiquitin | 6 | 2023 | 839 | 0.580 |
Why?
|
| Cancer Vaccines | 9 | 2019 | 1051 | 0.570 |
Why?
|
| Killer Cells, Natural | 10 | 2024 | 2201 | 0.570 |
Why?
|
| Antibodies, Bispecific | 3 | 2024 | 196 | 0.560 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2017 | 106 | 0.550 |
Why?
|
| Alleles | 6 | 2021 | 6864 | 0.550 |
Why?
|
| Antigens, Neoplasm | 8 | 2018 | 1993 | 0.540 |
Why?
|
| T-Lymphocytes | 18 | 2024 | 10194 | 0.540 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2017 | 647 | 0.530 |
Why?
|
| Neoplasm Transplantation | 18 | 2016 | 2016 | 0.530 |
Why?
|
| Th2 Cells | 1 | 2021 | 1060 | 0.530 |
Why?
|
| Drug Synergism | 29 | 2020 | 1757 | 0.530 |
Why?
|
| DNA Repair | 10 | 2018 | 2046 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 10 | 2024 | 1406 | 0.530 |
Why?
|
| Sulfonamides | 3 | 2024 | 1979 | 0.530 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2015 | 15 | 0.520 |
Why?
|
| Bone Diseases | 7 | 2022 | 418 | 0.520 |
Why?
|
| Jejunal Neoplasms | 1 | 2015 | 19 | 0.520 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2015 | 25 | 0.520 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2018 | 828 | 0.520 |
Why?
|
| Peptides | 9 | 2018 | 4358 | 0.510 |
Why?
|
| Viral Proteins | 7 | 2002 | 1804 | 0.510 |
Why?
|
| Genetic Heterogeneity | 5 | 2022 | 732 | 0.500 |
Why?
|
| Vietnam Conflict | 1 | 2015 | 100 | 0.500 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2024 | 1642 | 0.500 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2021 | 988 | 0.500 |
Why?
|
| High Mobility Group Proteins | 6 | 2001 | 177 | 0.500 |
Why?
|
| Aged | 106 | 2024 | 169310 | 0.490 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 4 | 2018 | 83 | 0.490 |
Why?
|
| Chromosomes, Human, Pair 14 | 6 | 2018 | 287 | 0.490 |
Why?
|
| Maytansine | 6 | 2021 | 86 | 0.490 |
Why?
|
| Herbicides | 1 | 2015 | 105 | 0.490 |
Why?
|
| Salvage Therapy | 12 | 2021 | 1263 | 0.480 |
Why?
|
| Male | 145 | 2024 | 360846 | 0.480 |
Why?
|
| Promoter Regions, Genetic | 9 | 2021 | 5790 | 0.480 |
Why?
|
| Arsenicals | 4 | 2002 | 118 | 0.480 |
Why?
|
| Interferon-beta | 4 | 2001 | 345 | 0.470 |
Why?
|
| Chromosome Aberrations | 12 | 2022 | 1768 | 0.470 |
Why?
|
| Cell Adhesion | 25 | 2016 | 3088 | 0.470 |
Why?
|
| Heavy Chain Disease | 2 | 2018 | 19 | 0.460 |
Why?
|
| Signal Transduction | 47 | 2021 | 23447 | 0.460 |
Why?
|
| Veterans Health | 1 | 2015 | 215 | 0.450 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2024 | 928 | 0.440 |
Why?
|
| Cell Transformation, Neoplastic | 11 | 2023 | 2827 | 0.440 |
Why?
|
| Oxides | 4 | 2002 | 401 | 0.430 |
Why?
|
| Down-Regulation | 20 | 2017 | 2919 | 0.430 |
Why?
|
| Apoptosis Regulatory Proteins | 10 | 2024 | 1136 | 0.420 |
Why?
|
| Lymph Nodes | 3 | 2018 | 3465 | 0.410 |
Why?
|
| Spiro Compounds | 3 | 2007 | 68 | 0.410 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2020 | 2425 | 0.410 |
Why?
|
| Receptors, Immunologic | 5 | 2014 | 1410 | 0.410 |
Why?
|
| Cell Division | 27 | 2013 | 4465 | 0.410 |
Why?
|
| Middle Aged | 112 | 2024 | 220921 | 0.400 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 5 | 2024 | 687 | 0.400 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2021 | 5672 | 0.400 |
Why?
|
| Clinical Trials as Topic | 16 | 2024 | 8002 | 0.400 |
Why?
|
| Esophageal Neoplasms | 6 | 2021 | 1654 | 0.400 |
Why?
|
| Immunotoxins | 3 | 2014 | 175 | 0.390 |
Why?
|
| Oligonucleotides | 5 | 2021 | 582 | 0.390 |
Why?
|
| Gene Regulatory Networks | 3 | 2021 | 1745 | 0.390 |
Why?
|
| HLA-A2 Antigen | 4 | 2013 | 211 | 0.390 |
Why?
|
| Anabolic Agents | 1 | 2014 | 256 | 0.390 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 432 | 0.390 |
Why?
|
| Cytokines | 21 | 2018 | 7396 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2020 | 4580 | 0.380 |
Why?
|
| Female | 131 | 2024 | 392705 | 0.380 |
Why?
|
| Necrobiotic Xanthogranuloma | 1 | 2011 | 10 | 0.380 |
Why?
|
| Piperidines | 7 | 2021 | 1656 | 0.380 |
Why?
|
| Barrett Esophagus | 4 | 2013 | 492 | 0.380 |
Why?
|
| Myeloid Cells | 3 | 2013 | 823 | 0.380 |
Why?
|
| Caspases | 20 | 2018 | 879 | 0.380 |
Why?
|
| Neoplasms, Experimental | 2 | 2016 | 1229 | 0.370 |
Why?
|
| Simian virus 40 | 3 | 2002 | 291 | 0.370 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2020 | 2917 | 0.370 |
Why?
|
| Survival Rate | 24 | 2021 | 12723 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 4 | 4 | 2017 | 375 | 0.360 |
Why?
|
| Recombination, Genetic | 4 | 2011 | 1519 | 0.360 |
Why?
|
| Leukocytes, Mononuclear | 8 | 2023 | 1844 | 0.360 |
Why?
|
| Phosphorylcholine | 8 | 2011 | 153 | 0.360 |
Why?
|
| Cytotoxicity, Immunologic | 8 | 2019 | 1351 | 0.360 |
Why?
|
| Cytogenetics | 4 | 2020 | 198 | 0.360 |
Why?
|
| Rad51 Recombinase | 6 | 2018 | 189 | 0.360 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 1388 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 10 | 2009 | 225 | 0.350 |
Why?
|
| RNA, Small Interfering | 15 | 2017 | 3430 | 0.350 |
Why?
|
| Sarcoma, Kaposi | 5 | 2018 | 374 | 0.350 |
Why?
|
| Recurrence | 23 | 2021 | 8466 | 0.350 |
Why?
|
| Cyclin-Dependent Kinases | 6 | 2023 | 655 | 0.350 |
Why?
|
| Adenocarcinoma | 10 | 2023 | 6345 | 0.340 |
Why?
|
| Leukemia, Plasma Cell | 2 | 2022 | 46 | 0.340 |
Why?
|
| Treatment Outcome | 54 | 2024 | 64685 | 0.340 |
Why?
|
| B-Lymphocytes | 13 | 2022 | 4758 | 0.340 |
Why?
|
| SUMO-1 Protein | 1 | 2009 | 35 | 0.340 |
Why?
|
| Herpesvirus 8, Human | 3 | 2020 | 255 | 0.340 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 2 | 2020 | 72 | 0.330 |
Why?
|
| Remission Induction | 14 | 2017 | 2397 | 0.330 |
Why?
|
| RNA Splicing | 5 | 2019 | 918 | 0.330 |
Why?
|
| Flow Cytometry | 19 | 2021 | 5870 | 0.330 |
Why?
|
| Cell Movement | 16 | 2024 | 5205 | 0.330 |
Why?
|
| MAP Kinase Signaling System | 7 | 2015 | 1486 | 0.320 |
Why?
|
| Quantitative Trait Loci | 2 | 2022 | 2116 | 0.320 |
Why?
|
| Epitopes | 2 | 2021 | 2503 | 0.320 |
Why?
|
| Cell Communication | 9 | 2023 | 1657 | 0.320 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 9 | 2017 | 441 | 0.310 |
Why?
|
| Cell Line | 20 | 2014 | 15601 | 0.310 |
Why?
|
| Transfection | 19 | 2021 | 5774 | 0.310 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 3 | 2018 | 40 | 0.310 |
Why?
|
| Combined Modality Therapy | 24 | 2020 | 8527 | 0.300 |
Why?
|
| RNA Interference | 9 | 2021 | 2832 | 0.300 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2015 | 3779 | 0.300 |
Why?
|
| DNA Mutational Analysis | 8 | 2020 | 4111 | 0.300 |
Why?
|
| Immunosuppressive Agents | 9 | 2018 | 4176 | 0.300 |
Why?
|
| Trans-Activators | 8 | 2017 | 2856 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 7 | 2017 | 2811 | 0.300 |
Why?
|
| Immunotherapy, Active | 1 | 2007 | 59 | 0.290 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 768 | 0.290 |
Why?
|
| Antineoplastic Agents, Alkylating | 8 | 2018 | 617 | 0.290 |
Why?
|
| Bone Marrow Transplantation | 11 | 2018 | 2693 | 0.290 |
Why?
|
| Disease Progression | 21 | 2022 | 13510 | 0.290 |
Why?
|
| Renal Insufficiency | 4 | 2023 | 809 | 0.290 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1853 | 0.280 |
Why?
|
| RNA, Messenger | 19 | 2021 | 12794 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 30 | 2019 | 10766 | 0.280 |
Why?
|
| Peptide Fragments | 4 | 2013 | 5112 | 0.280 |
Why?
|
| Chromosome Deletion | 7 | 2021 | 1386 | 0.280 |
Why?
|
| Adult | 80 | 2024 | 221210 | 0.280 |
Why?
|
| Acrylamides | 4 | 2018 | 260 | 0.280 |
Why?
|
| Antigens, CD | 6 | 2021 | 4001 | 0.280 |
Why?
|
| Autoantigens | 2 | 2009 | 891 | 0.270 |
Why?
|
| Thymidine Kinase | 2 | 1997 | 286 | 0.270 |
Why?
|
| Lymphocyte Activation | 11 | 2021 | 5485 | 0.270 |
Why?
|
| Population Groups | 1 | 2007 | 208 | 0.270 |
Why?
|
| Receptors, CXCR4 | 3 | 2019 | 727 | 0.270 |
Why?
|
| Immunoglobulin gamma-Chains | 2 | 2008 | 33 | 0.270 |
Why?
|
| Gene Knockdown Techniques | 5 | 2021 | 1612 | 0.270 |
Why?
|
| Neoplasms | 13 | 2024 | 22173 | 0.270 |
Why?
|
| Catechin | 1 | 2006 | 69 | 0.260 |
Why?
|
| Myeloma Proteins | 4 | 2011 | 71 | 0.260 |
Why?
|
| Gene Expression | 13 | 2020 | 7581 | 0.260 |
Why?
|
| Aged, 80 and over | 37 | 2021 | 58984 | 0.260 |
Why?
|
| DNA Replication | 7 | 2019 | 1418 | 0.260 |
Why?
|
| Epigenesis, Genetic | 8 | 2024 | 3801 | 0.260 |
Why?
|
| Osteonecrosis | 4 | 2014 | 229 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 14 | 2020 | 4514 | 0.260 |
Why?
|
| Transcription, Genetic | 11 | 2024 | 7593 | 0.260 |
Why?
|
| Histone Deacetylases | 7 | 2018 | 720 | 0.260 |
Why?
|
| DNA, Neoplasm | 6 | 2020 | 1745 | 0.260 |
Why?
|
| Transplantation, Heterologous | 15 | 2010 | 2386 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 17 | 2013 | 2457 | 0.260 |
Why?
|
| GTP Phosphohydrolases | 3 | 2020 | 517 | 0.250 |
Why?
|
| Transduction, Genetic | 4 | 2021 | 903 | 0.250 |
Why?
|
| Phosphorylation | 25 | 2013 | 8321 | 0.250 |
Why?
|
| Zebrafish | 2 | 2016 | 3008 | 0.250 |
Why?
|
| Pyrazoles | 7 | 2016 | 2009 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-hck | 2 | 2022 | 46 | 0.250 |
Why?
|
| Occupational Exposure | 1 | 2015 | 1813 | 0.240 |
Why?
|
| Proteoglycans | 4 | 2005 | 803 | 0.240 |
Why?
|
| Immunoglobulin M | 4 | 2021 | 1526 | 0.240 |
Why?
|
| STAT3 Transcription Factor | 8 | 2017 | 871 | 0.240 |
Why?
|
| Genetic Vectors | 6 | 2021 | 3396 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2021 | 2872 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 10 | 2021 | 7391 | 0.240 |
Why?
|
| Neoplasm Staging | 14 | 2024 | 11120 | 0.240 |
Why?
|
| Insulin-Like Growth Factor I | 16 | 2010 | 1935 | 0.240 |
Why?
|
| Immunoglobulin kappa-Chains | 4 | 2017 | 169 | 0.240 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 974 | 0.240 |
Why?
|
| Drug Screening Assays, Antitumor | 10 | 2015 | 718 | 0.230 |
Why?
|
| Anthraquinones | 1 | 2004 | 41 | 0.230 |
Why?
|
| Loss of Heterozygosity | 4 | 2018 | 662 | 0.230 |
Why?
|
| Osteoblasts | 5 | 2016 | 1143 | 0.230 |
Why?
|
| Disease Models, Animal | 12 | 2019 | 18255 | 0.230 |
Why?
|
| Membrane Glycoproteins | 7 | 2021 | 3701 | 0.230 |
Why?
|
| Benzoquinones | 5 | 2013 | 198 | 0.230 |
Why?
|
| Protein Binding | 11 | 2018 | 9353 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2007 | 1246 | 0.230 |
Why?
|
| DNA Helicases | 3 | 2017 | 851 | 0.230 |
Why?
|
| E2F1 Transcription Factor | 3 | 2018 | 178 | 0.230 |
Why?
|
| Agammaglobulinemia | 2 | 2023 | 171 | 0.230 |
Why?
|
| Interferon Regulatory Factors | 2 | 2016 | 261 | 0.230 |
Why?
|
| Cell Cycle Proteins | 8 | 2022 | 3449 | 0.230 |
Why?
|
| Bone Remodeling | 4 | 2014 | 581 | 0.230 |
Why?
|
| Mutagenesis | 3 | 2018 | 1232 | 0.230 |
Why?
|
| Retinoblastoma Protein | 4 | 2012 | 672 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2014 | 3810 | 0.230 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2023 | 2510 | 0.220 |
Why?
|
| beta Catenin | 5 | 2015 | 1040 | 0.220 |
Why?
|
| Evolution, Molecular | 5 | 2023 | 1886 | 0.220 |
Why?
|
| Genes, bcl-2 | 2 | 2003 | 119 | 0.220 |
Why?
|
| src-Family Kinases | 3 | 2022 | 535 | 0.220 |
Why?
|
| Proteins | 7 | 2023 | 6032 | 0.220 |
Why?
|
| DNA | 9 | 2017 | 7213 | 0.220 |
Why?
|
| Cyclophosphamide | 9 | 2023 | 2220 | 0.220 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2018 | 1394 | 0.210 |
Why?
|
| Blotting, Western | 14 | 2017 | 5035 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2022 | 17904 | 0.210 |
Why?
|
| Azepines | 2 | 2018 | 329 | 0.210 |
Why?
|
| Maximum Tolerated Dose | 5 | 2021 | 883 | 0.210 |
Why?
|
| Lactams, Macrocyclic | 5 | 2013 | 318 | 0.210 |
Why?
|
| Coculture Techniques | 13 | 2016 | 1341 | 0.210 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 789 | 0.210 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 58 | 0.210 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2024 | 1076 | 0.210 |
Why?
|
| Gene Expression Regulation | 10 | 2013 | 11904 | 0.210 |
Why?
|
| Medical Oncology | 3 | 2013 | 2321 | 0.210 |
Why?
|
| Aminopyridines | 2 | 2018 | 573 | 0.210 |
Why?
|
| Gene Dosage | 5 | 2018 | 1218 | 0.200 |
Why?
|
| Oxazoles | 1 | 2004 | 199 | 0.200 |
Why?
|
| Transplantation Conditioning | 4 | 2007 | 1590 | 0.200 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2009 | 1974 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 11 | 2016 | 426 | 0.200 |
Why?
|
| Genes, p53 | 2 | 2015 | 712 | 0.200 |
Why?
|
| Recombinant Proteins | 12 | 2013 | 6534 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2021 | 1374 | 0.200 |
Why?
|
| bcl-X Protein | 2 | 2018 | 410 | 0.200 |
Why?
|
| Caspase 3 | 7 | 2016 | 731 | 0.200 |
Why?
|
| Enzyme Activation | 14 | 2012 | 3597 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2021 | 1509 | 0.200 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2017 | 101 | 0.200 |
Why?
|
| Th1 Cells | 2 | 2021 | 1036 | 0.200 |
Why?
|
| Bone Resorption | 5 | 2014 | 723 | 0.190 |
Why?
|
| Lysine | 3 | 2021 | 993 | 0.190 |
Why?
|
| RNA, Neoplasm | 4 | 2018 | 750 | 0.190 |
Why?
|
| Luminescent Measurements | 3 | 2014 | 342 | 0.190 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 263 | 0.190 |
Why?
|
| Vaccines, Subunit | 2 | 2012 | 161 | 0.190 |
Why?
|
| Cell Differentiation | 13 | 2021 | 11530 | 0.190 |
Why?
|
| Education | 3 | 2019 | 537 | 0.190 |
Why?
|
| DNA, Intergenic | 1 | 2022 | 105 | 0.190 |
Why?
|
| Survival Analysis | 16 | 2022 | 10090 | 0.190 |
Why?
|
| Porphyrins | 1 | 2003 | 352 | 0.190 |
Why?
|
| Cell Transformation, Viral | 2 | 2003 | 526 | 0.190 |
Why?
|
| Genome-Wide Association Study | 5 | 2018 | 12690 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 13 | 7 | 2021 | 192 | 0.190 |
Why?
|
| Consensus | 5 | 2023 | 3124 | 0.190 |
Why?
|
| Hematologic Diseases | 3 | 2021 | 496 | 0.190 |
Why?
|
| Heterocyclic Compounds | 3 | 2019 | 246 | 0.190 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 2 | 2018 | 55 | 0.190 |
Why?
|
| Disease Management | 5 | 2024 | 2508 | 0.190 |
Why?
|
| Mice, Inbred NOD | 7 | 2021 | 1827 | 0.190 |
Why?
|
| Cells, Cultured | 19 | 2018 | 18966 | 0.190 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2002 | 257 | 0.180 |
Why?
|
| Single-Cell Analysis | 3 | 2023 | 2451 | 0.180 |
Why?
|
| Benzimidazoles | 4 | 2015 | 858 | 0.180 |
Why?
|
| Immunoglobulin Idiotypes | 4 | 2007 | 200 | 0.180 |
Why?
|
| Pinocytosis | 1 | 2001 | 62 | 0.180 |
Why?
|
| Endonucleases | 2 | 2020 | 371 | 0.180 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2001 | 1841 | 0.180 |
Why?
|
| Fatigue | 4 | 2022 | 1552 | 0.180 |
Why?
|
| Immunoblotting | 11 | 2015 | 1646 | 0.180 |
Why?
|
| I-kappa B Kinase | 5 | 2009 | 250 | 0.180 |
Why?
|
| Genes, Viral | 1 | 2002 | 649 | 0.180 |
Why?
|
| Antigen Presentation | 3 | 2007 | 1251 | 0.180 |
Why?
|
| Sirolimus | 5 | 2014 | 1533 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2015 | 418 | 0.180 |
Why?
|
| Sequence Analysis, RNA | 3 | 2018 | 2021 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 7 | 2013 | 6075 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2024 | 2898 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2018 | 15936 | 0.170 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 1896 | 0.170 |
Why?
|
| Urea | 2 | 2013 | 443 | 0.170 |
Why?
|
| Adenovirus E1B Proteins | 1 | 1999 | 14 | 0.170 |
Why?
|
| Immune Tolerance | 3 | 2018 | 2302 | 0.170 |
Why?
|
| Focal Adhesion Kinase 2 | 3 | 2014 | 87 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2018 | 3080 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 4 | 2021 | 6214 | 0.170 |
Why?
|
| Whole-Body Irradiation | 2 | 2000 | 433 | 0.170 |
Why?
|
| Adenine | 3 | 2021 | 987 | 0.170 |
Why?
|
| Ganciclovir | 2 | 1997 | 252 | 0.170 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2000 | 145 | 0.170 |
Why?
|
| Lymphokines | 4 | 2002 | 927 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 2 | 2022 | 940 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2018 | 410 | 0.170 |
Why?
|
| HeLa Cells | 7 | 2003 | 3094 | 0.170 |
Why?
|
| Genome, Human | 3 | 2019 | 4425 | 0.160 |
Why?
|
| Base Sequence | 7 | 2023 | 12441 | 0.160 |
Why?
|
| Endothelial Growth Factors | 3 | 2002 | 673 | 0.160 |
Why?
|
| INDEL Mutation | 1 | 2020 | 266 | 0.160 |
Why?
|
| Karyotyping | 6 | 2013 | 1171 | 0.160 |
Why?
|
| Pyrimidines | 7 | 2024 | 3028 | 0.160 |
Why?
|
| K562 Cells | 5 | 2013 | 642 | 0.160 |
Why?
|
| Transcription Factor DP1 | 1 | 2018 | 136 | 0.160 |
Why?
|
| Indoles | 5 | 2011 | 1833 | 0.160 |
Why?
|
| Up-Regulation | 12 | 2020 | 4125 | 0.160 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 405 | 0.160 |
Why?
|
| Repressor Proteins | 4 | 2022 | 2986 | 0.160 |
Why?
|
| NAD | 2 | 2013 | 614 | 0.160 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 383 | 0.160 |
Why?
|
| Nuclear Proteins | 7 | 2009 | 5799 | 0.160 |
Why?
|
| Mice, Nude | 4 | 2017 | 3614 | 0.160 |
Why?
|
| Exons | 2 | 2022 | 2391 | 0.150 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2018 | 62 | 0.150 |
Why?
|
| Cell Polarity | 1 | 2021 | 636 | 0.150 |
Why?
|
| Galectins | 1 | 2021 | 295 | 0.150 |
Why?
|
| Cell Death | 6 | 2016 | 1679 | 0.150 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 12 | 0.150 |
Why?
|
| Quality of Life | 6 | 2024 | 13367 | 0.150 |
Why?
|
| Heat-Shock Proteins | 8 | 2008 | 795 | 0.150 |
Why?
|
| Cohort Studies | 8 | 2022 | 41495 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 5 | 2012 | 473 | 0.150 |
Why?
|
| Phenotype | 7 | 2020 | 16592 | 0.150 |
Why?
|
| Immunophenotyping | 4 | 2019 | 1869 | 0.150 |
Why?
|
| Jaw Diseases | 2 | 2009 | 92 | 0.150 |
Why?
|
| Follow-Up Studies | 18 | 2023 | 39106 | 0.150 |
Why?
|
| RNA Precursors | 1 | 2019 | 212 | 0.150 |
Why?
|
| Receptors, Interleukin-6 | 5 | 2005 | 225 | 0.150 |
Why?
|
| Cisplatin | 4 | 2020 | 1652 | 0.150 |
Why?
|
| Lymphoma | 3 | 2021 | 1901 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 5 | 2012 | 477 | 0.150 |
Why?
|
| Cytoskeletal Proteins | 3 | 2002 | 1342 | 0.150 |
Why?
|
| Nuclear Factor 45 Protein | 1 | 2017 | 5 | 0.150 |
Why?
|
| DNA, Complementary | 5 | 2013 | 1991 | 0.150 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 85 | 0.150 |
Why?
|
| Acetylation | 6 | 2016 | 1055 | 0.150 |
Why?
|
| Secondary Prevention | 2 | 2014 | 1475 | 0.150 |
Why?
|
| Stavudine | 1 | 1997 | 85 | 0.150 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2017 | 31 | 0.150 |
Why?
|
| Thioguanine | 1 | 1997 | 45 | 0.140 |
Why?
|
| Immunoglobulin G | 7 | 2021 | 4544 | 0.140 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2018 | 239 | 0.140 |
Why?
|
| DNA, Recombinant | 1 | 1997 | 455 | 0.140 |
Why?
|
| Amino Acid Substitution | 2 | 2019 | 1739 | 0.140 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2022 | 727 | 0.140 |
Why?
|
| Virus Assembly | 1 | 1997 | 139 | 0.140 |
Why?
|
| Polyadenylation | 1 | 2018 | 117 | 0.140 |
Why?
|
| Membrane Proteins | 6 | 2021 | 7859 | 0.140 |
Why?
|
| Congresses as Topic | 2 | 2019 | 803 | 0.140 |
Why?
|
| Immunologic Memory | 4 | 2018 | 1359 | 0.140 |
Why?
|
| Binding Sites | 5 | 2016 | 6056 | 0.140 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2021 | 615 | 0.140 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2017 | 129 | 0.140 |
Why?
|
| Parvovirus B19, Human | 2 | 1996 | 40 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2021 | 2048 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2015 | 4576 | 0.140 |
Why?
|
| Gene Transfer Techniques | 2 | 1999 | 1206 | 0.140 |
Why?
|
| DNA, Viral | 3 | 2002 | 2202 | 0.140 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2016 | 91 | 0.140 |
Why?
|
| Risk Factors | 12 | 2022 | 74213 | 0.140 |
Why?
|
| Models, Biological | 10 | 2018 | 9469 | 0.130 |
Why?
|
| Receptors, Chemokine | 1 | 1999 | 652 | 0.130 |
Why?
|
| Allosteric Regulation | 2 | 2017 | 426 | 0.130 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2018 | 461 | 0.130 |
Why?
|
| Purines | 3 | 2010 | 607 | 0.130 |
Why?
|
| Tumor Burden | 8 | 2015 | 1892 | 0.130 |
Why?
|
| Mitochondrial Proteins | 4 | 2006 | 976 | 0.130 |
Why?
|
| Chromatin | 3 | 2023 | 2961 | 0.130 |
Why?
|
| Protein Subunits | 2 | 2018 | 943 | 0.130 |
Why?
|
| Etodolac | 2 | 2006 | 19 | 0.130 |
Why?
|
| Drug Administration Schedule | 10 | 2018 | 4853 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2021 | 1173 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 6 | 2001 | 629 | 0.130 |
Why?
|
| Cytarabine | 2 | 1999 | 698 | 0.130 |
Why?
|
| Stress, Physiological | 3 | 2012 | 1403 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2016 | 228 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 1010 | 0.130 |
Why?
|
| Immunomodulation | 2 | 2020 | 549 | 0.130 |
Why?
|
| Zidovudine | 1 | 1997 | 624 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 1405 | 0.120 |
Why?
|
| Antigens, CD34 | 6 | 2005 | 658 | 0.120 |
Why?
|
| Clodronic Acid | 2 | 2013 | 59 | 0.120 |
Why?
|
| Penetrance | 1 | 2017 | 383 | 0.120 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2015 | 71 | 0.120 |
Why?
|
| Multienzyme Complexes | 6 | 2003 | 666 | 0.120 |
Why?
|
| Natural Language Processing | 1 | 2024 | 1163 | 0.120 |
Why?
|
| Cell Growth Processes | 3 | 2011 | 384 | 0.120 |
Why?
|
| Introns | 1 | 2018 | 981 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 4 | 2012 | 285 | 0.120 |
Why?
|
| Cyclophilin A | 1 | 2015 | 58 | 0.120 |
Why?
|
| Adenoviridae | 1 | 1999 | 1085 | 0.120 |
Why?
|
| Graft vs Tumor Effect | 2 | 2005 | 68 | 0.120 |
Why?
|
| Internationality | 1 | 2020 | 1001 | 0.120 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 3 | 1996 | 48 | 0.120 |
Why?
|
| Genotype | 3 | 2018 | 12990 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 1551 | 0.120 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2016 | 171 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2017 | 356 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2015 | 152 | 0.120 |
Why?
|
| Biphenyl Compounds | 2 | 2012 | 1007 | 0.120 |
Why?
|
| Growth Inhibitors | 3 | 2002 | 378 | 0.120 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 4 | 2012 | 303 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 4 | 2008 | 1134 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2021 | 4399 | 0.120 |
Why?
|
| Casein Kinase Ialpha | 1 | 2014 | 26 | 0.120 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1994 | 42 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 9 | 2013 | 2645 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2010 | 2865 | 0.120 |
Why?
|
| Sulfonylurea Compounds | 2 | 1993 | 219 | 0.120 |
Why?
|
| Cell Degranulation | 2 | 2012 | 277 | 0.120 |
Why?
|
| Doxorubicin | 9 | 2018 | 2224 | 0.120 |
Why?
|
| Lymphotoxin-beta | 1 | 2014 | 14 | 0.120 |
Why?
|
| Lymphocytes | 4 | 2004 | 2612 | 0.120 |
Why?
|
| Genome, Mitochondrial | 1 | 2014 | 66 | 0.120 |
Why?
|
| Pseudogenes | 1 | 2014 | 104 | 0.120 |
Why?
|
| Drug Therapy, Combination | 7 | 2014 | 6312 | 0.120 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2015 | 282 | 0.110 |
Why?
|
| Chemokine CCL20 | 1 | 2014 | 64 | 0.110 |
Why?
|
| RNA, Antisense | 2 | 2013 | 136 | 0.110 |
Why?
|
| Antibodies | 3 | 2007 | 2418 | 0.110 |
Why?
|
| Receptors, CCR6 | 1 | 2014 | 74 | 0.110 |
Why?
|
| Hematopoiesis | 3 | 2020 | 2050 | 0.110 |
Why?
|
| DNA, Mitochondrial | 2 | 2020 | 865 | 0.110 |
Why?
|
| Databases, Genetic | 2 | 2018 | 1742 | 0.110 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2014 | 133 | 0.110 |
Why?
|
| Cryoglobulinemia | 2 | 2012 | 84 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 4740 | 0.110 |
Why?
|
| Neural Cell Adhesion Molecules | 2 | 2004 | 122 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2008 | 343 | 0.110 |
Why?
|
| Antigens, Surface | 2 | 2009 | 1606 | 0.110 |
Why?
|
| Genes, APC | 1 | 2014 | 145 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2023 | 891 | 0.110 |
Why?
|
| Societies, Medical | 3 | 2020 | 3905 | 0.110 |
Why?
|
| Infusions, Intravenous | 6 | 2019 | 2217 | 0.110 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 50 | 0.110 |
Why?
|
| Ikaros Transcription Factor | 2 | 2013 | 232 | 0.110 |
Why?
|
| Computational Biology | 4 | 2021 | 3517 | 0.110 |
Why?
|
| Protein Multimerization | 1 | 2018 | 983 | 0.110 |
Why?
|
| Receptors, Growth Factor | 3 | 2006 | 326 | 0.110 |
Why?
|
| Histones | 6 | 2024 | 2580 | 0.110 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 129 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2017 | 2805 | 0.110 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 184 | 0.110 |
Why?
|
| Triazoles | 1 | 2018 | 903 | 0.110 |
Why?
|
| Genes, Reporter | 2 | 2016 | 1529 | 0.110 |
Why?
|
| B-Cell Activating Factor | 3 | 2008 | 115 | 0.110 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2013 | 57 | 0.110 |
Why?
|
| HMGA1a Protein | 4 | 2001 | 61 | 0.110 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1994 | 189 | 0.110 |
Why?
|
| Receptors, Cell Surface | 3 | 2012 | 2822 | 0.110 |
Why?
|
| Osteogenesis | 3 | 2009 | 1273 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 3615 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2015 | 1062 | 0.110 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2013 | 93 | 0.110 |
Why?
|
| Genes, ras | 1 | 2015 | 654 | 0.110 |
Why?
|
| Protein Kinase C | 2 | 2008 | 1202 | 0.110 |
Why?
|
| Interferon-gamma | 3 | 2015 | 3162 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 504 | 0.100 |
Why?
|
| Acetylcysteine | 2 | 2003 | 260 | 0.100 |
Why?
|
| Sirtuins | 1 | 2015 | 320 | 0.100 |
Why?
|
| Pain | 4 | 2022 | 5073 | 0.100 |
Why?
|
| Estradiol | 4 | 2004 | 1937 | 0.100 |
Why?
|
| Pyridines | 4 | 2012 | 2875 | 0.100 |
Why?
|
| Mesna | 1 | 1992 | 62 | 0.100 |
Why?
|
| Interleukin-3 | 2 | 2014 | 425 | 0.100 |
Why?
|
| Dysgerminoma | 1 | 1992 | 66 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2021 | 641 | 0.100 |
Why?
|
| Cryoglobulins | 1 | 2012 | 58 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2012 | 368 | 0.100 |
Why?
|
| Fractures, Spontaneous | 1 | 2014 | 231 | 0.100 |
Why?
|
| Polyploidy | 1 | 2013 | 119 | 0.100 |
Why?
|
| Acyltransferases | 2 | 2005 | 305 | 0.100 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 3763 | 0.100 |
Why?
|
| Karyopherins | 1 | 2013 | 133 | 0.100 |
Why?
|
| Genetic Testing | 2 | 2017 | 3537 | 0.100 |
Why?
|
| Amino Acid Sequence | 5 | 2017 | 13446 | 0.100 |
Why?
|
| Molecular Sequence Data | 8 | 2013 | 17635 | 0.100 |
Why?
|
| Cluster Analysis | 6 | 2022 | 2707 | 0.100 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 235 | 0.100 |
Why?
|
| Syndecans | 4 | 2005 | 75 | 0.100 |
Why?
|
| Models, Genetic | 3 | 2019 | 3442 | 0.100 |
Why?
|
| Benzamides | 2 | 2015 | 1371 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2009 | 621 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2024 | 1860 | 0.100 |
Why?
|
| Prevalence | 3 | 2021 | 15733 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 2009 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1089 | 0.100 |
Why?
|
| Inflammation | 3 | 2024 | 10774 | 0.100 |
Why?
|
| Cysteine Endopeptidases | 6 | 2003 | 551 | 0.100 |
Why?
|
| Erythroid Precursor Cells | 1 | 1993 | 211 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2014 | 694 | 0.100 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2011 | 21 | 0.100 |
Why?
|
| Immunization | 3 | 2013 | 1227 | 0.100 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2012 | 74 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 1881 | 0.100 |
Why?
|
| Ifosfamide | 1 | 1992 | 232 | 0.100 |
Why?
|
| CD40 Ligand | 4 | 2006 | 522 | 0.100 |
Why?
|
| RNA Polymerase II | 2 | 2021 | 539 | 0.100 |
Why?
|
| Adenovirus E1A Proteins | 2 | 2002 | 74 | 0.100 |
Why?
|
| Positron-Emission Tomography | 6 | 2016 | 6484 | 0.100 |
Why?
|
| Herpesvirus 1, Human | 1 | 1997 | 753 | 0.100 |
Why?
|
| Intestinal Neoplasms | 1 | 2014 | 314 | 0.100 |
Why?
|
| Phenylalanine | 1 | 2013 | 366 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 682 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2017 | 1175 | 0.090 |
Why?
|
| Lymphocyte Transfusion | 2 | 2003 | 232 | 0.090 |
Why?
|
| Spleen | 3 | 2008 | 2295 | 0.090 |
Why?
|
| Point Mutation | 2 | 2019 | 1595 | 0.090 |
Why?
|
| Administration, Oral | 8 | 2018 | 4021 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 855 | 0.090 |
Why?
|
| Autophagy | 5 | 2024 | 1327 | 0.090 |
Why?
|
| Interferon-alpha | 3 | 2001 | 921 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2014 | 750 | 0.090 |
Why?
|
| Hematuria | 1 | 1992 | 233 | 0.090 |
Why?
|
| Mitochondria | 7 | 2020 | 3624 | 0.090 |
Why?
|
| Linkage Disequilibrium | 1 | 2016 | 1998 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2017 | 1745 | 0.090 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2010 | 92 | 0.090 |
Why?
|
| RNA | 3 | 2014 | 2725 | 0.090 |
Why?
|
| Case-Control Studies | 10 | 2021 | 22176 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 1993 | 212 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 11076 | 0.090 |
Why?
|
| Immunity, Cellular | 3 | 2021 | 1560 | 0.090 |
Why?
|
| Alu Elements | 1 | 2011 | 115 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2017 | 2057 | 0.090 |
Why?
|
| Transplantation, Homologous | 7 | 2009 | 4807 | 0.090 |
Why?
|
| United States | 8 | 2024 | 72340 | 0.090 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 365 | 0.090 |
Why?
|
| beta 2-Microglobulin | 5 | 2005 | 329 | 0.090 |
Why?
|
| Iodine Radioisotopes | 1 | 1994 | 1031 | 0.090 |
Why?
|
| Endoribonucleases | 1 | 2012 | 228 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 1943 | 0.090 |
Why?
|
| Interleukin-2 | 2 | 2013 | 1889 | 0.090 |
Why?
|
| Software | 3 | 2017 | 4434 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 5 | 2014 | 2065 | 0.090 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 476 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 946 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 1378 | 0.090 |
Why?
|
| Polymers | 2 | 2023 | 1616 | 0.090 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2009 | 30 | 0.090 |
Why?
|
| Cell Nucleus | 4 | 2003 | 2910 | 0.090 |
Why?
|
| Bone Transplantation | 2 | 2005 | 929 | 0.090 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 82 | 0.090 |
Why?
|
| Lysosomes | 1 | 2015 | 924 | 0.090 |
Why?
|
| CREB-Binding Protein | 2 | 2001 | 148 | 0.090 |
Why?
|
| Bone and Bones | 3 | 2009 | 2568 | 0.090 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2012 | 280 | 0.080 |
Why?
|
| Plasmids | 2 | 2014 | 2269 | 0.080 |
Why?
|
| Substrate Specificity | 4 | 2019 | 1791 | 0.080 |
Why?
|
| Glycoproteins | 2 | 2016 | 2203 | 0.080 |
Why?
|
| Retrospective Studies | 14 | 2024 | 80647 | 0.080 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 68 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 1899 | 0.080 |
Why?
|
| Dental Fistula | 1 | 2009 | 12 | 0.080 |
Why?
|
| 3' Untranslated Regions | 3 | 2018 | 519 | 0.080 |
Why?
|
| Algorithms | 4 | 2024 | 14033 | 0.080 |
Why?
|
| Nanoparticles | 2 | 2019 | 1958 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2016 | 3606 | 0.080 |
Why?
|
| Time Factors | 18 | 2019 | 39969 | 0.080 |
Why?
|
| Cyclin D1 | 2 | 2009 | 451 | 0.080 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2010 | 332 | 0.080 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 455 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 2 | 2012 | 934 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 583 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1964 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2013 | 799 | 0.080 |
Why?
|
| Ligands | 6 | 2018 | 3272 | 0.080 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 531 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2009 | 69 | 0.080 |
Why?
|
| Acetyltransferases | 2 | 2001 | 231 | 0.080 |
Why?
|
| Gene Targeting | 1 | 2012 | 838 | 0.080 |
Why?
|
| Carrier Proteins | 4 | 2023 | 4937 | 0.080 |
Why?
|
| Flavones | 1 | 2009 | 68 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2002 | 439 | 0.080 |
Why?
|
| Tyrosine | 3 | 2003 | 1440 | 0.080 |
Why?
|
| Immunization, Passive | 3 | 2005 | 616 | 0.080 |
Why?
|
| Lac Operon | 2 | 1999 | 237 | 0.080 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2008 | 66 | 0.080 |
Why?
|
| Quinazolinones | 1 | 2010 | 221 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 858 | 0.080 |
Why?
|
| Activins | 1 | 2010 | 210 | 0.080 |
Why?
|
| ras Proteins | 1 | 2014 | 1054 | 0.080 |
Why?
|
| Macromolecular Substances | 3 | 2000 | 1434 | 0.080 |
Why?
|
| Phosphoproteins | 3 | 2011 | 2448 | 0.080 |
Why?
|
| Lentivirus | 4 | 2014 | 508 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1924 | 0.080 |
Why?
|
| Benzylamines | 3 | 2019 | 247 | 0.080 |
Why?
|
| Blood Component Removal | 1 | 2009 | 132 | 0.080 |
Why?
|
| Histone Acetyltransferases | 2 | 2001 | 336 | 0.080 |
Why?
|
| Antigens, Viral | 2 | 2021 | 988 | 0.080 |
Why?
|
| Germinal Center | 2 | 2021 | 380 | 0.080 |
Why?
|
| Thiophenes | 1 | 2012 | 569 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2006 | 748 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 561 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2023 | 9319 | 0.070 |
Why?
|
| Hydroxyurea | 2 | 2001 | 284 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 411 | 0.070 |
Why?
|
| Sequence Deletion | 2 | 2013 | 1494 | 0.070 |
Why?
|
| Pyrroles | 2 | 2020 | 1125 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 1640 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2008 | 95 | 0.070 |
Why?
|
| Niacinamide | 1 | 2010 | 413 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2006 | 4352 | 0.070 |
Why?
|
| Consensus Development Conferences as Topic | 3 | 2014 | 168 | 0.070 |
Why?
|
| RNA-Binding Proteins | 2 | 2023 | 1898 | 0.070 |
Why?
|
| Immunity | 3 | 2021 | 996 | 0.070 |
Why?
|
| Spinal Neoplasms | 1 | 2014 | 716 | 0.070 |
Why?
|
| Natural Killer T-Cells | 1 | 2010 | 322 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1052 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2002 | 678 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 20100 | 0.070 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2006 | 11 | 0.070 |
Why?
|
| Growth Substances | 2 | 2006 | 768 | 0.070 |
Why?
|
| Mutation, Missense | 2 | 2014 | 2571 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2020 | 1334 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2273 | 0.070 |
Why?
|
| Tetanus Toxoid | 1 | 2007 | 189 | 0.070 |
Why?
|
| Aphidicolin | 2 | 2001 | 37 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2024 | 4811 | 0.070 |
Why?
|
| Receptors, Laminin | 1 | 2006 | 26 | 0.070 |
Why?
|
| Phorbol Esters | 1 | 2006 | 108 | 0.070 |
Why?
|
| Authorship | 1 | 2010 | 284 | 0.070 |
Why?
|
| Prospective Studies | 7 | 2023 | 54423 | 0.070 |
Why?
|
| Cytotoxins | 1 | 2007 | 153 | 0.070 |
Why?
|
| Mice, Transgenic | 6 | 2020 | 9542 | 0.070 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2006 | 80 | 0.070 |
Why?
|
| Incidence | 6 | 2015 | 21355 | 0.070 |
Why?
|
| Lymphatic Diseases | 1 | 2008 | 320 | 0.070 |
Why?
|
| Caspase 9 | 5 | 2005 | 185 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2006 | 169 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6484 | 0.070 |
Why?
|
| Gene Rearrangement | 1 | 2011 | 1125 | 0.070 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 439 | 0.060 |
Why?
|
| Injections, Subcutaneous | 2 | 2018 | 681 | 0.060 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2006 | 108 | 0.060 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 129 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2008 | 443 | 0.060 |
Why?
|
| Superoxides | 2 | 2004 | 387 | 0.060 |
Why?
|
| I-kappa B Proteins | 4 | 2009 | 211 | 0.060 |
Why?
|
| Rifabutin | 1 | 2005 | 59 | 0.060 |
Why?
|
| Neutropenia | 4 | 2009 | 885 | 0.060 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 2529 | 0.060 |
Why?
|
| Hydrolases | 1 | 2006 | 147 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2003 | 188 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2009 | 3492 | 0.060 |
Why?
|
| Paraproteins | 1 | 2005 | 38 | 0.060 |
Why?
|
| Precipitin Tests | 2 | 2003 | 813 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 487 | 0.060 |
Why?
|
| Lactones | 1 | 2007 | 317 | 0.060 |
Why?
|
| Cytidine Deaminase | 2 | 2020 | 243 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2020 | 5079 | 0.060 |
Why?
|
| Hematology | 2 | 2019 | 243 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 554 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2008 | 852 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 3 | 2019 | 1351 | 0.060 |
Why?
|
| Chromosomes, Human | 2 | 2019 | 441 | 0.060 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2005 | 138 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 1252 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 10508 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2017 | 36426 | 0.060 |
Why?
|
| Tea | 1 | 2006 | 288 | 0.060 |
Why?
|
| Glucocorticoids | 4 | 2009 | 2161 | 0.060 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2004 | 106 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 1997 | 3060 | 0.060 |
Why?
|
| Piperazines | 3 | 2009 | 2523 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2006 | 296 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2014 | 2467 | 0.060 |
Why?
|
| Thrombocytopenia | 3 | 2020 | 1182 | 0.060 |
Why?
|
| Etoposide | 5 | 1999 | 634 | 0.060 |
Why?
|
| Isoantibodies | 1 | 2008 | 674 | 0.060 |
Why?
|
| Disclosure | 1 | 2010 | 748 | 0.060 |
Why?
|
| Oleanolic Acid | 1 | 2003 | 43 | 0.060 |
Why?
|
| Mutagens | 2 | 2015 | 179 | 0.060 |
Why?
|
| Quinolines | 1 | 2009 | 765 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2010 | 3429 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 7968 | 0.050 |
Why?
|
| Reactive Oxygen Species | 3 | 2018 | 2139 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 3 | 2009 | 352 | 0.050 |
Why?
|
| Neck | 1 | 2008 | 734 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2009 | 3397 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 1787 | 0.050 |
Why?
|
| Drug Industry | 1 | 2010 | 788 | 0.050 |
Why?
|
| Calreticulin | 1 | 2024 | 114 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2004 | 170 | 0.050 |
Why?
|
| Stem Cells | 4 | 2010 | 3524 | 0.050 |
Why?
|
| Anti-HIV Agents | 2 | 2009 | 4527 | 0.050 |
Why?
|
| Phylogeny | 2 | 2022 | 2811 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2002 | 1626 | 0.050 |
Why?
|
| Cell Count | 2 | 2017 | 1835 | 0.050 |
Why?
|
| Caveolae | 1 | 2002 | 55 | 0.050 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2004 | 155 | 0.050 |
Why?
|
| Deoxyribonuclease I | 1 | 2003 | 224 | 0.050 |
Why?
|
| Graft Survival | 3 | 2007 | 3820 | 0.050 |
Why?
|
| Mast Cells | 2 | 2008 | 1392 | 0.050 |
Why?
|
| Tubulin | 1 | 2006 | 693 | 0.050 |
Why?
|
| Carboplatin | 3 | 2020 | 794 | 0.050 |
Why?
|
| Centrosome | 1 | 2024 | 209 | 0.050 |
Why?
|
| Discitis | 1 | 2003 | 45 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2012 | 2496 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 3597 | 0.050 |
Why?
|
| Drug Resistance | 3 | 2003 | 1596 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2002 | 58 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 585 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2011 | 629 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 178 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 2539 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2023 | 185 | 0.050 |
Why?
|
| Clone Cells | 2 | 2018 | 1659 | 0.050 |
Why?
|
| Trisomy | 2 | 2013 | 260 | 0.050 |
Why?
|
| Deoxyribonucleases | 1 | 2023 | 211 | 0.050 |
Why?
|
| Respirovirus | 1 | 2001 | 31 | 0.050 |
Why?
|
| Vaccination | 3 | 2022 | 3384 | 0.050 |
Why?
|
| Health Status | 1 | 2015 | 4077 | 0.050 |
Why?
|
| RANK Ligand | 3 | 2008 | 318 | 0.050 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 858 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2022 | 2643 | 0.050 |
Why?
|
| Twins, Monozygotic | 1 | 2003 | 470 | 0.050 |
Why?
|
| Protein Kinases | 2 | 2009 | 1608 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2015 | 616 | 0.050 |
Why?
|
| Antigens | 1 | 2007 | 1443 | 0.050 |
Why?
|
| Environment | 1 | 2007 | 1123 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2003 | 446 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2021 | 56 | 0.050 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2021 | 27 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5440 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 1349 | 0.050 |
Why?
|
| Helper Viruses | 1 | 2001 | 40 | 0.050 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2001 | 69 | 0.050 |
Why?
|
| Antigenic Variation | 1 | 2021 | 118 | 0.050 |
Why?
|
| Blood Group Incompatibility | 1 | 2002 | 135 | 0.050 |
Why?
|
| Seizures | 1 | 2014 | 2957 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2002 | 641 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2021 | 67 | 0.050 |
Why?
|
| Camptothecin | 1 | 2004 | 591 | 0.050 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2001 | 207 | 0.050 |
Why?
|
| G-Quadruplexes | 1 | 2003 | 143 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 4415 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2021 | 114 | 0.050 |
Why?
|
| Tissue Donors | 3 | 2005 | 2332 | 0.050 |
Why?
|
| Isoquinolines | 2 | 2017 | 352 | 0.050 |
Why?
|
| Ubiquitination | 2 | 2017 | 1007 | 0.050 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2022 | 165 | 0.040 |
Why?
|
| Polyneuropathies | 2 | 2014 | 137 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 20568 | 0.040 |
Why?
|
| E2F Transcription Factors | 1 | 2001 | 269 | 0.040 |
Why?
|
| Internet | 1 | 2013 | 3093 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 909 | 0.040 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2001 | 150 | 0.040 |
Why?
|
| HEK293 Cells | 3 | 2014 | 4281 | 0.040 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2004 | 335 | 0.040 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2001 | 153 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8656 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 422 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2009 | 2557 | 0.040 |
Why?
|
| Membrane Potentials | 4 | 2004 | 1090 | 0.040 |
Why?
|
| Young Adult | 5 | 2024 | 59260 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 22174 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2000 | 176 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2012 | 2057 | 0.040 |
Why?
|
| Epirubicin | 1 | 2000 | 81 | 0.040 |
Why?
|
| Immunoglobulin A | 2 | 2001 | 978 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 2 | 2003 | 1078 | 0.040 |
Why?
|
| Nephritis | 1 | 2020 | 145 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2012 | 3549 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2021 | 404 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2001 | 346 | 0.040 |
Why?
|
| Phthalazines | 1 | 2002 | 383 | 0.040 |
Why?
|
| Gene Library | 2 | 2018 | 1059 | 0.040 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2000 | 120 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2008 | 2767 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2021 | 2665 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2022 | 341 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2012 | 3066 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2001 | 4142 | 0.040 |
Why?
|
| Membrane Microdomains | 2 | 2015 | 206 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2003 | 458 | 0.040 |
Why?
|
| Genetics | 1 | 2020 | 114 | 0.040 |
Why?
|
| Tumor Lysis Syndrome | 1 | 1999 | 38 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 866 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 12973 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 114 | 0.040 |
Why?
|
| TCF Transcription Factors | 2 | 2012 | 138 | 0.040 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2000 | 186 | 0.040 |
Why?
|
| Chloroquine | 1 | 2001 | 274 | 0.040 |
Why?
|
| Skin Diseases | 2 | 2007 | 1094 | 0.040 |
Why?
|
| Electroporation | 1 | 2021 | 255 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2002 | 380 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2005 | 2571 | 0.040 |
Why?
|
| Diploidy | 2 | 2013 | 132 | 0.040 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 1999 | 16 | 0.040 |
Why?
|
| Anemia | 1 | 2009 | 1509 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2021 | 1060 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2020 | 293 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2001 | 453 | 0.040 |
Why?
|
| Transcription Factors, TFII | 1 | 1999 | 62 | 0.040 |
Why?
|
| Cytochrome c Group | 3 | 2003 | 122 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2021 | 244 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2021 | 522 | 0.040 |
Why?
|
| Chromatin Assembly Factor-1 | 1 | 1998 | 21 | 0.040 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2000 | 203 | 0.040 |
Why?
|
| Caspase 8 | 3 | 2005 | 190 | 0.040 |
Why?
|
| Organelles | 1 | 2001 | 266 | 0.040 |
Why?
|
| RNA Editing | 1 | 2020 | 151 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2018 | 1802 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14665 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2003 | 149 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1463 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 2 | 2007 | 1601 | 0.040 |
Why?
|
| Kinetics | 3 | 2017 | 6374 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 1704 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2008 | 1366 | 0.040 |
Why?
|
| Boron Compounds | 1 | 2020 | 182 | 0.040 |
Why?
|
| Bayes Theorem | 2 | 2019 | 2330 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2018 | 95 | 0.040 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2018 | 38 | 0.040 |
Why?
|
| Mitosis | 1 | 2024 | 1188 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 1999 | 316 | 0.040 |
Why?
|
| Transcription Factor TFIID | 1 | 1999 | 150 | 0.040 |
Why?
|
| Proteomics | 2 | 2023 | 3848 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 1999 | 104 | 0.040 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2018 | 23 | 0.040 |
Why?
|
| Gene Products, tat | 1 | 1998 | 111 | 0.040 |
Why?
|
| Chemokine CCL3 | 2 | 2008 | 84 | 0.040 |
Why?
|
| Methylation | 1 | 2021 | 1084 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 497 | 0.040 |
Why?
|
| Aging | 5 | 2021 | 8710 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2013 | 1990 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2024 | 23996 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2330 | 0.040 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 620 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2023 | 765 | 0.040 |
Why?
|
| Biopsy | 3 | 2019 | 6766 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2013 | 1968 | 0.040 |
Why?
|
| Oncogene Proteins v-fos | 1 | 2017 | 16 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 569 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1998 | 158 | 0.040 |
Why?
|
| Neomycin | 1 | 1997 | 92 | 0.040 |
Why?
|
| Zalcitabine | 1 | 1997 | 43 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 345 | 0.040 |
Why?
|
| Ubiquitins | 1 | 1999 | 366 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 1076 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2000 | 778 | 0.040 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2017 | 82 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 1171 | 0.040 |
Why?
|
| Acid Phosphatase | 2 | 2007 | 139 | 0.040 |
Why?
|
| Phenanthrolines | 1 | 2017 | 50 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 1625 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 10212 | 0.040 |
Why?
|
| Ribavirin | 1 | 1999 | 395 | 0.040 |
Why?
|
| Isoenzymes | 3 | 2007 | 1687 | 0.040 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2008 | 105 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2018 | 222 | 0.040 |
Why?
|
| Bone Marrow Examination | 2 | 2012 | 155 | 0.040 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2017 | 41 | 0.040 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2017 | 32 | 0.040 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 1120 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2018 | 270 | 0.040 |
Why?
|
| Blood Cells | 1 | 1999 | 305 | 0.040 |
Why?
|
| Stomatitis | 1 | 2000 | 271 | 0.040 |
Why?
|
| Skin | 1 | 2011 | 4484 | 0.040 |
Why?
|
| International Cooperation | 2 | 2014 | 1422 | 0.040 |
Why?
|
| Moloney murine leukemia virus | 1 | 1997 | 109 | 0.040 |
Why?
|
| Radiography | 1 | 2008 | 6965 | 0.030 |
Why?
|
| Nucleosides | 1 | 1997 | 131 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2018 | 261 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 1999 | 819 | 0.030 |
Why?
|
| Mitochondrial Diseases | 1 | 2020 | 343 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 489 | 0.030 |
Why?
|
| Retroviridae | 1 | 1999 | 850 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 2007 | 186 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2009 | 1126 | 0.030 |
Why?
|
| Glycine | 1 | 2020 | 663 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 1036 | 0.030 |
Why?
|
| CpG Islands | 1 | 2021 | 1230 | 0.030 |
Why?
|
| COS Cells | 1 | 1998 | 1130 | 0.030 |
Why?
|
| Acyclovir | 1 | 1997 | 268 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 980 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1999 | 420 | 0.030 |
Why?
|
| Ploidies | 1 | 2017 | 285 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2001 | 937 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 2850 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2007 | 293 | 0.030 |
Why?
|
| Leukocyte Transfusion | 1 | 1996 | 56 | 0.030 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2015 | 39 | 0.030 |
Why?
|
| Graft vs Host Reaction | 1 | 1996 | 102 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 713 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 1626 | 0.030 |
Why?
|
| Epigenomics | 1 | 2021 | 943 | 0.030 |
Why?
|
| Luminescent Proteins | 3 | 2003 | 837 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2015 | 105 | 0.030 |
Why?
|
| Homeodomain Proteins | 3 | 2013 | 2418 | 0.030 |
Why?
|
| Biological Products | 1 | 2024 | 914 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 373 | 0.030 |
Why?
|
| Amyloidosis | 2 | 2003 | 817 | 0.030 |
Why?
|
| Receptors, KIR | 1 | 2015 | 110 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2017 | 372 | 0.030 |
Why?
|
| Multivariate Analysis | 4 | 2020 | 12059 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2018 | 616 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 44 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1997 | 825 | 0.030 |
Why?
|
| Erythrocyte Indices | 1 | 2015 | 144 | 0.030 |
Why?
|
| Rats, Inbred ACI | 1 | 1994 | 34 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 1999 | 366 | 0.030 |
Why?
|
| Nimodipine | 1 | 2014 | 56 | 0.030 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 781 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2001 | 1170 | 0.030 |
Why?
|
| Base Composition | 1 | 2014 | 290 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 1997 | 559 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2011 | 857 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 805 | 0.030 |
Why?
|
| Hypertension | 1 | 2014 | 8540 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1993 | 5314 | 0.030 |
Why?
|
| Oximes | 1 | 2015 | 303 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 1809 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2014 | 2927 | 0.030 |
Why?
|
| Thymidine | 1 | 1994 | 299 | 0.030 |
Why?
|
| Risk | 2 | 2017 | 9610 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 1997 | 298 | 0.030 |
Why?
|
| Lymphocyte Depletion | 2 | 2012 | 602 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2003 | 1407 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 1997 | 694 | 0.030 |
Why?
|
| Piracetam | 1 | 2014 | 88 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2020 | 1132 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 613 | 0.030 |
Why?
|
| Tritium | 1 | 1994 | 708 | 0.030 |
Why?
|
| Myeloablative Agonists | 2 | 2007 | 209 | 0.030 |
Why?
|
| France | 1 | 2015 | 497 | 0.030 |
Why?
|
| Phase Transition | 1 | 2013 | 71 | 0.030 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 2013 | 17 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2015 | 6345 | 0.030 |
Why?
|
| Actins | 2 | 2015 | 2050 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 345 | 0.030 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2014 | 200 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1997 | 803 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2020 | 9647 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2013 | 184 | 0.030 |
Why?
|
| Nootropic Agents | 1 | 2014 | 157 | 0.030 |
Why?
|
| Vidarabine | 1 | 2014 | 336 | 0.030 |
Why?
|
| Paracrine Communication | 2 | 2006 | 277 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2019 | 2226 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2012 | 91 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 1999 | 13381 | 0.030 |
Why?
|
| Solutions | 1 | 2013 | 412 | 0.030 |
Why?
|
| Densitometry | 1 | 2012 | 151 | 0.030 |
Why?
|
| Fibronectins | 2 | 2009 | 723 | 0.030 |
Why?
|
| Buffers | 1 | 2012 | 146 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 12463 | 0.030 |
Why?
|
| Reference Values | 2 | 2014 | 4920 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 1158 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 2013 | 434 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 2 | 2005 | 213 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14417 | 0.030 |
Why?
|
| Antimetabolites | 1 | 2012 | 129 | 0.030 |
Why?
|
| Fever | 1 | 2000 | 1618 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2005 | 380 | 0.020 |
Why?
|
| Vaccines, DNA | 1 | 2013 | 286 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 14608 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2013 | 205 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2012 | 248 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 370 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 964 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 1998 | 3792 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2012 | 145 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 360 | 0.020 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2014 | 303 | 0.020 |
Why?
|
| Crystallization | 1 | 2012 | 534 | 0.020 |
Why?
|
| Leucine | 1 | 2013 | 548 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2022 | 4243 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2012 | 1058 | 0.020 |
Why?
|
| Cell Separation | 1 | 1997 | 1720 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 126 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2012 | 384 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 602 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 4369 | 0.020 |
Why?
|
| Proline | 1 | 2013 | 457 | 0.020 |
Why?
|
| Drosophila | 1 | 1998 | 1495 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 1200 | 0.020 |
Why?
|
| Vinblastine | 1 | 1992 | 488 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 26129 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2014 | 916 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2011 | 159 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 656 | 0.020 |
Why?
|
| Virion | 1 | 1993 | 422 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 1091 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 578 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2015 | 12341 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1993 | 410 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2013 | 456 | 0.020 |
Why?
|
| HIV-1 | 2 | 1998 | 6863 | 0.020 |
Why?
|
| Twins | 1 | 2012 | 339 | 0.020 |
Why?
|
| Caregivers | 1 | 2022 | 2238 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 470 | 0.020 |
Why?
|
| Androstadienes | 1 | 2012 | 348 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2735 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 400 | 0.020 |
Why?
|
| DNA Footprinting | 2 | 2000 | 97 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2010 | 294 | 0.020 |
Why?
|
| Subtraction Technique | 2 | 2003 | 512 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2013 | 449 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 234 | 0.020 |
Why?
|
| Forecasting | 2 | 2012 | 2928 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 802 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1994 | 2264 | 0.020 |
Why?
|
| Linear Models | 1 | 2020 | 5872 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3156 | 0.020 |
Why?
|
| Templates, Genetic | 1 | 1990 | 189 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2010 | 145 | 0.020 |
Why?
|
| Immune System | 1 | 2015 | 796 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2012 | 903 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 426 | 0.020 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2009 | 32 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 178 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 191 | 0.020 |
Why?
|
| Data Mining | 1 | 2014 | 551 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 1990 | 311 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1990 | 340 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 252 | 0.020 |
Why?
|
| Lung | 1 | 2008 | 10002 | 0.020 |
Why?
|
| Pedigree | 1 | 2017 | 4542 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 4915 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 1229 | 0.020 |
Why?
|
| Protein Isoforms | 2 | 2006 | 1699 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2009 | 53 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2009 | 148 | 0.020 |
Why?
|
| Diterpenes | 1 | 1990 | 171 | 0.020 |
Why?
|
| Genome, Viral | 1 | 1993 | 667 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2010 | 248 | 0.020 |
Why?
|
| Urochordata | 1 | 2008 | 19 | 0.020 |
Why?
|
| Periodontal Pocket | 1 | 2009 | 171 | 0.020 |
Why?
|
| Integrin alpha4beta1 | 1 | 2009 | 119 | 0.020 |
Why?
|
| Kv1.5 Potassium Channel | 1 | 2008 | 5 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 390 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1999 | 1909 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2008 | 65 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 326 | 0.020 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 316 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 3733 | 0.020 |
Why?
|
| Virus Replication | 1 | 1996 | 2435 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 151 | 0.020 |
Why?
|
| Pneumonia | 1 | 2000 | 2143 | 0.020 |
Why?
|
| Research Design | 1 | 2024 | 6180 | 0.020 |
Why?
|
| Chemokines | 1 | 2012 | 959 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 2007 | 184 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 2395 | 0.020 |
Why?
|
| Granulocytes | 2 | 2001 | 551 | 0.020 |
Why?
|
| Seawater | 1 | 2008 | 124 | 0.020 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 126 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2008 | 76 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 176 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2015 | 1336 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2007 | 121 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 779 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2009 | 229 | 0.020 |
Why?
|
| Dromaiidae | 1 | 2007 | 7 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 2650 | 0.020 |
Why?
|
| Cell Membrane | 2 | 2009 | 3687 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2013 | 819 | 0.020 |
Why?
|
| Cathepsins | 1 | 2008 | 241 | 0.020 |
Why?
|
| Albumins | 1 | 2010 | 575 | 0.020 |
Why?
|
| Hypergammaglobulinemia | 1 | 2007 | 71 | 0.020 |
Why?
|
| Brain | 1 | 2014 | 27121 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 1994 | 2898 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 1563 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1115 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2002 | 664 | 0.020 |
Why?
|
| Thrombocytosis | 1 | 2007 | 89 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2016 | 2632 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2008 | 295 | 0.020 |
Why?
|
| Morpholines | 1 | 2010 | 581 | 0.020 |
Why?
|
| Temperature | 1 | 2013 | 2226 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2008 | 321 | 0.020 |
Why?
|
| Iron | 1 | 2015 | 1793 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 1186 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 198 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 1154 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 598 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3165 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2022 | 4481 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 3688 | 0.020 |
Why?
|
| Ribonucleotide Reductases | 1 | 2006 | 76 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2013 | 1400 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 1498 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 1416 | 0.020 |
Why?
|
| Acute Disease | 1 | 1997 | 7237 | 0.020 |
Why?
|
| Family | 1 | 2017 | 3195 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2008 | 392 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 589 | 0.020 |
Why?
|
| Leukocytosis | 1 | 2007 | 251 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2008 | 389 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15266 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 1528 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2006 | 152 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2010 | 899 | 0.020 |
Why?
|
| Sepsis | 1 | 2000 | 2585 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2006 | 107 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2006 | 298 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3201 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 213 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 4431 | 0.020 |
Why?
|
| Somatomedins | 1 | 2006 | 179 | 0.020 |
Why?
|
| Critical Illness | 1 | 2018 | 2723 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2001 | 1596 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 15843 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2005 | 1520 | 0.020 |
Why?
|
| raf Kinases | 1 | 2005 | 118 | 0.020 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 60 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2005 | 340 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2206 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 364 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 882 | 0.020 |
Why?
|
| G2 Phase | 1 | 2005 | 136 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4251 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 4244 | 0.020 |
Why?
|
| Breast Neoplasms | 4 | 2011 | 21019 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5337 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2011 | 2048 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 823 | 0.010 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2004 | 60 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2024 | 0.010 |
Why?
|
| Contactins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2014 | 1906 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2005 | 614 | 0.010 |
Why?
|
| Phosphoric Acids | 1 | 2003 | 20 | 0.010 |
Why?
|
| Caspase 7 | 1 | 2003 | 50 | 0.010 |
Why?
|
| Lasers | 1 | 2008 | 952 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 613 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2007 | 1152 | 0.010 |
Why?
|
| Graft vs Host Disease | 3 | 2003 | 3029 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2004 | 191 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2004 | 173 | 0.010 |
Why?
|
| Liver | 1 | 1999 | 7528 | 0.010 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2003 | 105 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1134 | 0.010 |
Why?
|
| Health | 1 | 2006 | 398 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2005 | 431 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3826 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2003 | 93 | 0.010 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2003 | 66 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 2003 | 79 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2013 | 5439 | 0.010 |
Why?
|
| Anthracenes | 1 | 2003 | 83 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 2004 | 162 | 0.010 |
Why?
|
| Receptor Cross-Talk | 1 | 2003 | 116 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 1668 | 0.010 |
Why?
|
| Emotions | 1 | 2015 | 2739 | 0.010 |
Why?
|
| Physician's Role | 1 | 2010 | 917 | 0.010 |
Why?
|
| Metaphase | 1 | 2003 | 145 | 0.010 |
Why?
|
| Kidney Diseases | 2 | 2007 | 2091 | 0.010 |
Why?
|
| Rats | 2 | 2001 | 23741 | 0.010 |
Why?
|
| Depression | 1 | 2022 | 8126 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2003 | 206 | 0.010 |
Why?
|
| Phosphoserine | 1 | 2002 | 203 | 0.010 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2002 | 112 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2002 | 148 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 2003 | 239 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2005 | 503 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2002 | 170 | 0.010 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2002 | 27 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 506 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2011 | 2413 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2002 | 94 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2002 | 102 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2002 | 119 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 3359 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2002 | 70 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 452 | 0.010 |
Why?
|
| Macrophages | 1 | 1997 | 5767 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 372 | 0.010 |
Why?
|
| Palliative Care | 1 | 1997 | 3598 | 0.010 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2005 | 619 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2002 | 325 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2003 | 254 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 1336 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1702 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 192 | 0.010 |
Why?
|
| Splenectomy | 1 | 2003 | 391 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 3032 | 0.010 |
Why?
|
| Siblings | 1 | 2005 | 825 | 0.010 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2000 | 20 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2001 | 262 | 0.010 |
Why?
|
| Fluorescence | 1 | 2003 | 756 | 0.010 |
Why?
|
| Models, Animal | 1 | 2007 | 2112 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2013 | 2046 | 0.010 |
Why?
|
| Amides | 1 | 2003 | 449 | 0.010 |
Why?
|
| Proteinuria | 1 | 2004 | 607 | 0.010 |
Why?
|
| Necrosis | 1 | 2005 | 1611 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 2894 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2002 | 302 | 0.010 |
Why?
|
| Mental Health | 1 | 2015 | 3250 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2003 | 562 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 2003 | 735 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 852 | 0.010 |
Why?
|
| Bence Jones Protein | 1 | 1999 | 18 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2002 | 454 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2002 | 305 | 0.010 |
Why?
|
| Feasibility Studies | 2 | 2001 | 5247 | 0.010 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2000 | 113 | 0.010 |
Why?
|
| Rhodopsin | 1 | 2000 | 203 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2002 | 611 | 0.010 |
Why?
|
| Cytosol | 1 | 2003 | 888 | 0.010 |
Why?
|
| Globins | 1 | 2000 | 404 | 0.010 |
Why?
|
| Activating Transcription Factor 2 | 1 | 1999 | 44 | 0.010 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1866 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 1999 | 68 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 719 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1999 | 134 | 0.010 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 1999 | 92 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2002 | 594 | 0.010 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2002 | 287 | 0.010 |
Why?
|
| Serine | 1 | 2003 | 831 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2002 | 558 | 0.010 |
Why?
|
| Back Pain | 1 | 2003 | 545 | 0.010 |
Why?
|
| Cyclins | 1 | 2001 | 594 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2003 | 1395 | 0.010 |
Why?
|
| Protein Folding | 1 | 2002 | 870 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 1989 | 0.010 |
Why?
|
| Estrogens | 1 | 2005 | 1522 | 0.010 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 1998 | 39 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2003 | 754 | 0.010 |
Why?
|
| Paxillin | 1 | 1998 | 86 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 1998 | 73 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2002 | 727 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2001 | 638 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 361 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 1967 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1999 | 287 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1998 | 119 | 0.010 |
Why?
|
| Adolescent | 2 | 2024 | 88326 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2000 | 579 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2002 | 829 | 0.010 |
Why?
|
| Androgens | 1 | 2005 | 1286 | 0.010 |
Why?
|
| Platelet Count | 1 | 2001 | 781 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 1762 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 2477 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 2000 | 317 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 1349 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 3530 | 0.010 |
Why?
|
| Dimerization | 1 | 1999 | 891 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1999 | 270 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 1693 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2002 | 570 | 0.010 |
Why?
|
| KB Cells | 1 | 1996 | 13 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2000 | 790 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 1303 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 1999 | 502 | 0.010 |
Why?
|
| Thiotepa | 1 | 1996 | 66 | 0.010 |
Why?
|
| Bone Density | 1 | 2009 | 3551 | 0.010 |
Why?
|
| Vincristine | 1 | 1999 | 1036 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 3677 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2000 | 836 | 0.010 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2004 | 1609 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 1999 | 438 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1996 | 851 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 1517 | 0.010 |
Why?
|
| Antioxidants | 1 | 2003 | 1668 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1995 | 777 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 1616 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2005 | 2557 | 0.010 |
Why?
|
| Haplorhini | 1 | 1995 | 525 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 5722 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1999 | 664 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1272 | 0.010 |
Why?
|
| Luciferases | 1 | 1996 | 714 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 686 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1995 | 1545 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 2905 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 6938 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 4615 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2001 | 1796 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 2112 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 756 | 0.010 |
Why?
|
| Reoperation | 1 | 2001 | 4303 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1993 | 11122 | 0.010 |
Why?
|
| Retina | 1 | 2000 | 2659 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2002 | 4446 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1999 | 2479 | 0.000 |
Why?
|
| Logistic Models | 1 | 2002 | 13255 | 0.000 |
Why?
|
| Ventricular Function, Left | 1 | 2000 | 3879 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1999 | 8633 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 7406 | 0.000 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1993 | 1159 | 0.000 |
Why?
|
| Age Factors | 1 | 2001 | 18399 | 0.000 |
Why?
|
| Kidney | 1 | 1995 | 7048 | 0.000 |
Why?
|
| Child | 1 | 1999 | 80158 | 0.000 |
Why?
|